Search research articles
Contact Us
Filters
Showing results (141-150 of 322) with videos related to
Page
of 33
Sort By:
The New England Journal of Medicine
|
June 14, 2016
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 1, 2019
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia
David I Marks, Partow Kebriaei, Matthias Stelljes, et al.
Annals of Hematology
|
January 4, 2022
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes
Amer M Zeidan, Daniel J DeAngelo, Jeanne Palmer, et al.
Leukemia & Lymphoma
|
March 5, 2024
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy
Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner, et al.
Ejhaem
|
July 18, 2022
Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults
Anand Ashwin Patel, Joseph Heng, Emily Dworkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia
Olatoyosi M Odenike, Serhan Alkan, Dorie Sher, et al.
Blood
|
June 27, 2009
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)
Ivan M Borrello, Hyam I Levitsky, Wendy Stock, et al.
Blood Advances
|
February 4, 2020
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
Nitin Jain, Wendy Stock, Amer Zeidan, et al.
Blood Advances
|
August 16, 2022
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation
James Godfrey, Hongtao Liu, Jovian Yu, et al.
Blood
|
August 28, 2009
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse
Francis Giles, Norbert Vey, Daniel DeAngelo, et al.
Page
of 33
Search research articles
Search
Showing results (141-150 of 322) with videos related to
Sort By:
Page
of 33
The New England Journal of Medicine
|
June 14, 2016
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M Kantarjian, Daniel J DeAngelo, Matthias Stelljes, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 1, 2019
Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia
David I Marks, Partow Kebriaei, Matthias Stelljes, et al.
Annals of Hematology
|
January 4, 2022
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes
Amer M Zeidan, Daniel J DeAngelo, Jeanne Palmer, et al.
Leukemia & Lymphoma
|
March 5, 2024
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy
Rafael Madero-Marroquin, Emily Dworkin, Howard Weiner, et al.
Ejhaem
|
July 18, 2022
Efficacy and tolerability of a modified pediatric-inspired intensive regimen for acute lymphoblastic leukemia in older adults
Anand Ashwin Patel, Joseph Heng, Emily Dworkin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 5, 2008
Histone deacetylase inhibitor romidepsin has differential activity in core binding factor acute myeloid leukemia
Olatoyosi M Odenike, Serhan Alkan, Dorie Sher, et al.
Blood
|
June 27, 2009
Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML)
Ivan M Borrello, Hyam I Levitsky, Wendy Stock, et al.
Blood Advances
|
February 4, 2020
Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
Nitin Jain, Wendy Stock, Amer Zeidan, et al.
Blood Advances
|
August 16, 2022
Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation
James Godfrey, Hongtao Liu, Jovian Yu, et al.
Blood
|
August 28, 2009
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse
Francis Giles, Norbert Vey, Daniel DeAngelo, et al.
Page
of 33